TLPH vs. NRSN, INDP, AYTU, VBIV, NRBO, NERV, ORGS, TRAW, COCP, and AVTX
Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include NeuroSense Therapeutics (NRSN), Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), VBI Vaccines (VBIV), NeuroBo Pharmaceuticals (NRBO), Minerva Neurosciences (NERV), Orgenesis (ORGS), Traws Pharma (TRAW), Cocrystal Pharma (COCP), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
Talphera (NASDAQ:TLPH) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
37.7% of Talphera shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 3.0% of Talphera shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Talphera has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.
In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 5 mentions for NeuroSense Therapeutics and 4 mentions for Talphera. NeuroSense Therapeutics' average media sentiment score of 0.36 beat Talphera's score of 0.33 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.
Talphera currently has a consensus target price of $4.50, indicating a potential upside of 334.24%. Given Talphera's higher possible upside, equities research analysts clearly believe Talphera is more favorable than NeuroSense Therapeutics.
NeuroSense Therapeutics has lower revenue, but higher earnings than Talphera. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.
Talphera's return on equity of -71.67% beat NeuroSense Therapeutics' return on equity.
Talphera received 1 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users.
Summary
Talphera beats NeuroSense Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Talphera News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talphera Competitors List
Related Companies and Tools
